Email Alert RSS
Volume 14 Issue 6
Nov.  2023
Turn off MathJax
Article Contents
Abstract
References
QU Yang, ZHANG Yanna, ZHOU Yidong, SUN Qiang. Application of 21-gene Recurrence Score in Hormone Receptor Positive Breast Cancer Patients[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1274-1281. DOI: 10.12290/xhyxzz.2023-0226
Citation: QU Yang, ZHANG Yanna, ZHOU Yidong, SUN Qiang. Application of 21-gene Recurrence Score in Hormone Receptor Positive Breast Cancer Patients[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1274-1281. DOI: 10.12290/xhyxzz.2023-0226
shu

Application of 21-gene Recurrence Score in Hormone Receptor Positive Breast Cancer Patients

  • Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds: 

National High Level Hospital Clinical Research Funding 2022-PUMCH-B-039

More Information
  • Corresponding author:

    ZHOU Yidong, E-mail: zhouyd@pumch.cn

    SUN Qiang, E-mail: xhsunq@163.com

  • Received Date: May 06, 2023
  • Accepted Date: August 20, 2023
  • Issue Publish Date: November 29, 2023
    Graphical Abstract
    • Abstract
  • In the past decade, with the introduction of precision medicine, the treatment of breast cancer has entered a new era. It now tends towards the de-escalation and individualization of treatment plans, aiming to minimize iatrogenic toxicity while maximizing benefits for patients without compromising survival outcomes. The 21-gene assay evaluates the expression levels of 21 genes associated with breast cancer recurrence and provides a 21-gene recurrence score (RS) to assess the risk of recurrence and potential benefit from chemotherapy in breast cancer patients. Currently, RS is recommended by multiple guidelines such as the American Society of Clinical Oncology (ASCO), National Comprehensive Cancer Network (NCCN), and Chinese Anti-Cancer Association(CACA) for guiding adjuvant therapy in hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) early-stage breast cancer patients. However, there are still controversies surrounding its clinical application. Current research mainly focuses on optimizing RS to accurately identify patients who would benefit from adjuvant therapy, thus enabling more personalized treatment plans for breast cancer patients. This review provides an overview of the 21-gene assay, its application in HR+ breast cancer patients' adjuvant therapy, its impact on clinical decision-making, existing controversies regarding RS, and prospects for integrating RS with clinical pathological information. The aim is to guide further expansion of RS's application in clinical practice and achieve more precise adjuvant therapy for breast cancer patients.
    • FullText(HTML)
    • References (49)
  • [1]
    Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world[J]. Breast Cancer, 2019, 11: 151-164.
    [2]
    Kamal AH, Loprinzi CL, Reynolds C, et al. Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score[J]. Oncologist, 2011, 16: 1359-1366. DOI: 10.1634/theoncologist.2011-0048
    [3]
    Fisher B, Jeong JH, Bryant J, et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials[J]. Lancet, 2004, 364: 858-868. DOI: 10.1016/S0140-6736(04)16981-X
    [4]
    Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors[J]. N Engl J Med, 1989, 320: 479-484. DOI: 10.1056/NEJM198902233200802
    [5]
    Chia SK, Speers CH, Bryce CJ, et al. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies[J]. J Clin Oncol, 2004, 22: 1630-1637. DOI: 10.1200/JCO.2004.09.070
    [6]
    Sparano JA, Gray RJ, Makower DF, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer[J]. N Engl J Med, 2018, 379: 111-121. DOI: 10.1056/NEJMoa1804710
    [7]
    Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer[J]. J Natl Cancer Inst, 1997, 89: 1673-1682. DOI: 10.1093/jnci/89.22.1673
    [8]
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials[J]. Lancet, 2005, 365: 1687-1717. DOI: 10.1016/S0140-6736(05)66544-0
    [9]
    Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer[J]. J Clin Oncol, 2005, 23: 7265-7277. DOI: 10.1200/JCO.2005.02.0818
    [10]
    Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer[J]. N Engl J Med, 2004, 351: 2817-2826. DOI: 10.1056/NEJMoa041588
    [11]
    Sparano JA, Gray RJ, Makower DF, et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer[J]. N Engl J Med, 2015, 373: 2005-2014. DOI: 10.1056/NEJMoa1510764
    [12]
    Telli ML, Gradishar WJ, Ward JH. NCCN Guidelines Updates: Breast Cancer[J]. J Natl Compr Canc Netw, 2019, 17: 552-555.
    [13]
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100, 000 women in 123 randomised trials[J]. Lancet, 2012, 379: 432-444. DOI: 10.1016/S0140-6736(11)61625-5
    [14]
    Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial[J]. Lancet Oncol, 2010, 11: 55-65. DOI: 10.1016/S1470-2045(09)70314-6
    [15]
    Albain KS, Barlow WE, Ravdin PM, et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial[J]. Lancet, 2009, 374: 2055-2063. DOI: 10.1016/S0140-6736(09)61523-3
    [16]
    Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study[J]. J Clin Oncol, 2010, 28: 1829-1834. DOI: 10.1200/JCO.2009.24.4798
    [17]
    Gluz O, Nitz UA, Christgen M, et al. West German Study Group Phase Ⅲ PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment[J]. J Clin Oncol, 2016, 34: 2341-2349. DOI: 10.1200/JCO.2015.63.5383
    [18]
    Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer[J]. N Engl J Med, 2021, 385: 2336-2347. DOI: 10.1056/NEJMoa2108873
    [19]
    Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer[J]. J Clin Oncol, 2006, 24: 5769-5779. DOI: 10.1200/JCO.2006.07.2793
    [20]
    Sparano JA, Gray RJ, Ravdin PM, et al. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer[J]. N Engl J Med, 2019, 380: 2395-2405. DOI: 10.1056/NEJMoa1904819
    [21]
    Gradishar WJ, Moran MS, Abraham J, et al. NCCN GuidelinesⓇ Insights: Breast Cancer, Version 4.2023[J]. J Natl Compr Canc Netw, 2023, 21: 594-608. DOI: 10.6004/jnccn.2023.0031
    [22]
    Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer[J]. J Clin Oncol, 2006, 24: 3726-3734. DOI: 10.1200/JCO.2005.04.7985
    [23]
    Gradishar WJ, Moran MS, Abraham J, et al. NCCN GuidelinesⓇ Insights: Breast Cancer, Version 4.2021[J]. J Natl Compr Canc Netw, 2021, 19: 484-493. DOI: 10.6004/jnccn.2021.0023
    [24]
    Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2019, 30: 1194-1220. DOI: 10.1093/annonc/mdz173
    [25]
    Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017[J]. Ann Oncol, 2017, 28: 1700-1712. DOI: 10.1093/annonc/mdx308
    [26]
    中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志, 2021, 31: 954-1040. DOI: 10.19401/j.cnki.1007-3639.2021.10.013
    [27]
    Weldon CB, Trosman JR, Gradishar WJ, et al. Barriers to the use of personalized medicine in breast cancer[J]. J Oncol Pract, 2012, 8: e24-e31. DOI: 10.1200/JOP.2011.000448
    [28]
    Lyman GH, Cosler LE, Kuderer NM, et al. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies[J]. Cancer, 2007, 109: 1011-1018. DOI: 10.1002/cncr.22506
    [29]
    Gagliato Dde M, Gonzalez-Angulo AM, Lei X, et al. Clinical impact of delaying initiation of adjuvant chemother-apy in patients with breast cancer[J]. J Clin Oncol, 2014, 32: 735-744. DOI: 10.1200/JCO.2013.49.7693
    [30]
    Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer[J]. J Clin Oncol, 2011, 29: 4273-4278. DOI: 10.1200/JCO.2010.31.2835
    [31]
    Turner BM, Skinner KA, Tang P, et al. Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score[J]. Mod Pathol, 2015, 28: 921-931. DOI: 10.1038/modpathol.2015.50
    [32]
    Kim HS, Umbricht CB, Illei PB, et al. Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer[J]. J Clin Oncol, 2016, 34: 4390-4397. DOI: 10.1200/JCO.2016.67.7195
    [33]
    Lee SB, Kim J, Sohn G, et al. A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor-Positive, Human Epidermal Growth Factor 2 (HER2)-Negative Breast Cancer[J]. Cancer Res Treat, 2019, 51: 1073-1085. DOI: 10.4143/crt.2018.357
    [34]
    Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer[J]. J Clin Oncol, 2005, 23: 2716-2725. DOI: 10.1200/JCO.2005.06.178
    [35]
    Mook S, Schmidt MK, Rutgers EJ, et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study[J]. Lancet Oncol, 2009, 10: 1070-1076. DOI: 10.1016/S1470-2045(09)70254-2
    [36]
    Zhang Y, Zhou Y, Mao F, et al. Ki-67 index, progesterone receptor expression, histologic grade and tumor size in predicting breast cancer recurrence risk: A consecutive cohort study[J]. Cancer Commun, 2020, 40: 181-193. DOI: 10.1002/cac2.12024
    [37]
    Yoo SH, Kim TY, Kim M, et al. Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor-Positive Early Breast Cancer[J]. Clin Breast Cancer, 2020, 20: 98-107. e1. DOI: 10.1016/j.clbc.2019.07.010
    [38]
    Orucevic A, Bell JL, McNabb AP, et al. Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data[J]. Breast Cancer Res Treat, 2017, 163: 51-61. DOI: 10.1007/s10549-017-4170-3
    [39]
    Lee MH, Han W, Lee JE, et al. The clinical impact of 21-gene recurrence score on treatment decisions for patients with hormone receptor-positive early breast cancer in Korea[J]. Cancer Res Treat, 2015, 47: 208-214.
    [40]
    Leong SP, Shen ZZ, Liu TJ, et al. Is breast cancer the same disease in Asian and Western countries?[J]. World J Surg, 2010, 34: 2308-2324. DOI: 10.1007/s00268-010-0683-1
    [41]
    Polley MY, Leung SC, Gao D, et al. An international study to increase concordance in Ki67 scoring[J]. Modern Pathol, 2015, 28: 778-786. DOI: 10.1038/modpathol.2015.38
    [42]
    Tang G, Cuzick J, Costantino JP, et al. Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors[J]. J Clin Oncol, 2011, 29: 4365-4372. DOI: 10.1200/JCO.2011.35.3714
    [43]
    Sparano JA, Crager MR, Tang G, et al. Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer[J]. J Clin Oncol, 2021, 39: 557-564. DOI: 10.1200/JCO.20.03007
    [44]
    Boland MR, Al-Maksoud A, Ryan ÉJ, et al. Value of a 21-gene expression assay on core biopsy to predict neoadjuvant chemotherapy response in breast cancer: systematic review and meta-analysis[J]. Br J Surg, 2021, 108: 24-31. DOI: 10.1093/bjs/znaa048
    [45]
    Iwata H, Masuda N, Yamamoto Y, et al. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study[J]. Breast Cancer Res Treat, 2019, 173: 123-133. DOI: 10.1007/s10549-018-4964-y
    [46]
    Davey MG, Ryan ÉJ, Boland MR, et al. Clinical utility of the 21-gene assay in predicting response to neoadjuvant endocrine therapy in breast cancer: A systematic review and meta-analysis[J]. Breast, 2021, 58: 113-120. DOI: 10.1016/j.breast.2021.04.010
    [47]
    Slodkowska EA, Ross JS. MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients[J]. Expert Rev Mol Diagn, 2009, 9: 417-422. DOI: 10.1586/erm.09.32
    [48]
    Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer[J]. N Engl J Med, 2016, 375: 717-729. DOI: 10.1056/NEJMoa1602253
    [49]
    Henry NL, Somerfield MR, Abramson VG, et al. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline[J]. J Clin Oncol, 2019, 37: 1965-1977. DOI: 10.1200/JCO.19.00948
    • Related Articles

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (364) PDF downloads (51) Cited by()
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close